Sepsis Alliance Welcomes T2 Biosystems as Presenting Sponsor of Sepsis Tech & Innovation
June 7, 2021
Sepsis Tech & Innovation attendees will have the opportunity to engage with the nation’s leading innovators, clinicians, investors, and policymakers to discuss health technology and innovation, and discover its potential to reduce the burdens of sepsis, antimicrobial resistance, health inequity, and more.
“We are grateful to T2 Biosystems for their commitment to technology and innovation progress around sepsis diagnosis, treatment, and care, as well as their strong belief in the Sepsis Alliance mission,” said Thomas Heymann, Sepsis Alliance President and CEO. “It is only with this support that Sepsis Alliance is able to continue providing high-quality and free educational resources that will save lives and limbs from sepsis.”
“We’re honored to come together with Sepsis Alliance, which shares our goal to reduce the number of deaths associated with sepsis,” said CEO John Sperzel. “Rapid diagnostics are critical tools in the fight against sepsis, and we’re grateful to have the opportunity to educate the medical community on how our innovations can help improve outcomes.”
Catapulting off the success of the inaugural Sepsis Alliance Summit in late 2020, Sepsis Tech & Innovation is an opportunity for Sepsis Alliance to expand its voice in the health innovation and technology space, with the ultimate goal of taking the costly guesswork out of sepsis diagnosis and care.
The Sepsis Alliance Summit, Sepsis Alliance’s first foray into virtual conferences, attracted over 4,000 registrants and awarded thousands of nursing continuing education credit hours.
On Wednesday, June 23rd, during Sepsis Tech and Innovation, T2 Biosystems will deliver the Industry Keynote, “Breaking New Ground in Sepsis Diagnosis and Management with Non-Culture-Based Tests.” T2 Biosystems’ Panels provide results directly from a whole blood sample, often before the second dose of antibiotics is delivered. Dr. Aparna Ahuja will discuss the impact of sepsis on healthcare costs and patient outcomes as well as reviewing the growing challenge of antimicrobial resistance. Dr. Debbie Goff will discuss the critical importance of time to appropriate therapy in sepsis patients and how non-culture-based tests can improve patient outcomes. Attendees will gain insight on the current challenges in sepsis diagnosis and management and how improvements can be made with non-culture-based tests. Sepsis survivor case studies will also be shared.
To view the full Sepsis Tech & Innovation agenda, please click here.
To learn more and register for the event, please visit http://SepsisTech.org.
Sepsis Alliance, the first and leading sepsis organization in the U.S., seeks to save lives and reduce suffering by improving sepsis awareness and care. More than 1.7 million people are diagnosed with sepsis each year in the U.S. with more than 270,000 dying and over 50% of survivors experiencing post-sepsis syndrome and other lingering effects, including amputations. At Sepsis Alliance’s founding in 2003, only 19% of U.S. adults were aware of the term “sepsis.” After over ten years of educational efforts for the general public and healthcare providers through Sepsis.org, Sepsis Alliance Clinical Community, Sepsis Alliance Institute, and Sepsis Alliance Voices, awareness is at an all-time high of 71% with over 20,000 healthcare providers across the country having attended sepsis webinars and courses to elevate their practice and over 28 Sepsis Awareness Month state proclamations. Sepsis Alliance is a 501(c)3 nonprofit and a GuideStar Platinum Rated charity. For more information, please visit www.sepsis.org and connect with Sepsis Alliance on Facebook, Twitter, Instagram, and LinkedIn at @SepsisAlliance.